Adcytherix se lance et lève 30 millions d'euros en amorçage pour développer des anticorps-conjugués de nouvelle génération
June 11, 2024 00:00 ET
|
Adcytherix
Adcytherix se lance et lève 30 millions d'euros en amorçage pour développer des anticorps-conjugués de nouvelle génération L'objectif est de créer un leader dans le développement d'ADC pour traiter...
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates
June 11, 2024 00:00 ET
|
Adcytherix
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. ...
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
May 13, 2024 05:30 ET
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024 07:00 ET
|
ADC Therapeutics SA
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all...
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen...
The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035, claims Roots Analysis
October 11, 2022 13:40 ET
|
Roots Analysis
London, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. In order to...
Advanced Dermatology and Cosmetic Surgery Acquires Maragh Dermatology, Surgery and Vein Institute
April 05, 2022 09:00 ET
|
Advanced Dermatology and Cosmetic Surgery
WASHINGTON, April 05, 2022 (GLOBE NEWSWIRE) -- Advanced Dermatology and Cosmetic Surgery announces today Maragh Dermatology, Surgery and Vein Institute, (Maragh Dermatology), has joined its brand...
Advanced Dermatology and Cosmetic Surgery Chief Medical Officer Dr. Mark Kaufmann Assumes Presidency of the American Academy of Dermatology
March 25, 2022 14:19 ET
|
Advanced Dermatology and Cosmetic Surgery
MAITLAND, Fla., March 25, 2022 (GLOBE NEWSWIRE) -- Advanced Dermatology and Cosmetic Surgery announces that today, board-certified dermatologist Mark Kaufmann, MD, FAAD, begins his one-year term as...
Antibody Therapy Market Revenue to hit $445 Billion by 2028, Says Global Market Insights Inc.
February 22, 2022 03:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Global antibody therapy market value projected to cross USD 445 billion by 2028, according to a new research report by Global Market...